The multiple effects of fecal microbiota transplantation on diarrhea-predominant irritable bowel syndrome (IBS-D) patients with anxiety and depression behaviors

Microb Cell Fact. 2021 Dec 28;20(1):233. doi: 10.1186/s12934-021-01720-1.

Abstract

Background: Anxiety and depression are complications in Irritable bowel syndrome (IBS) patients. In this study, we recruited 18 IBS patients with mild-modest anxiety and depression behaviors, and after the screening, we defined the FMT treatment group (n = 9) and the control group (n = 9). The IBS symptom severity scale (IBS-SSS), Hamilton Anxiety Rating Scale (HAM-A), Hamilton Depression Rating Scale (HAM-D), Irritable Bowel Syndrome Quality of Life (IBS-QOL) and Bristol stool scale (BSS) were evaluated one week before FMT (baseline), one-week-, one-month-, two-month-, and three-month-following FMT. Meanwhile, we determined the SCFAs in the patient's feces and serum and continued the metagenomic analysis of the microorganisms in the patient's feces.

Results: The results showed that the patient's anxiety and depression behavior gradually improved with FMT treatment. Moreover, the illness and quality of life had also been relieved significantly. The content of isovaleric acid and valeric acid was significantly reduced in the FMT group compared to the Col group. Metagenomic analysis showed that FMT treatment decreased the abundance of Faecalibacterium, Eubacterium and Escherichia. From KEGG functional analysis, we confirmed that the top five abundant pathways were "bacterial chemotaxis, "flagellar assembly", "glycine, serine and threonine metabolism", "apoptosis", and "bacterial invasion of epithelial cells".

Conclusions: FMT treatment can effectively alleviate the anxiety and depression behaviors of IBS-D patients and reduce the IBS-SSS score, indicating that FMT can improve patients' symptoms. The high throughput sequencing results show that Bifidobacterium and Escherichia play the most critical role in the formation and recovery of IBS-D patients. The GC/MS data indicated that faeces isovaleric acid and valeric acid might be more suitable as a metabolic indicator of IBS-D remission. Trial registration ChiCTR, ChiCTR1900024924, Registered 3 August 2019, https://www.chictr.org.cn/showproj.aspx?proj=41676 .

Keywords: Anxiety and depression; Fecal microbiota transplantation; Irritable bowel syndrome; Metagenome; Short-chain fatty acids.

MeSH terms

  • Adult
  • Aged
  • Anxiety / microbiology*
  • Anxiety / therapy*
  • Depression / microbiology*
  • Depression / therapy*
  • Diarrhea / microbiology
  • Diarrhea / therapy
  • Escherichia / classification
  • Eubacterium / classification
  • Faecalibacterium / classification
  • Fecal Microbiota Transplantation*
  • Feces / microbiology
  • Female
  • Gastrointestinal Microbiome
  • Hemiterpenes / metabolism
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Irritable Bowel Syndrome / complications
  • Irritable Bowel Syndrome / microbiology*
  • Irritable Bowel Syndrome / therapy
  • Male
  • Metagenome*
  • Middle Aged
  • Pentanoic Acids / metabolism
  • Quality of Life

Substances

  • Hemiterpenes
  • Pentanoic Acids
  • isovaleric acid
  • n-pentanoic acid